Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 199.55B |
| Revenue (ttm) | 43.89B |
| Net Income (ttm) | 10.86B |
| Shares Out | 1.94B |
| EPS (ttm) | 5.45 |
| PE Ratio | 18.92 |
| Forward PE | 14.85 |
| Dividend | 3.50 (3.46%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 653,346 |
| Average Volume | 2,228,811 |
| Open | 102.82 |
| Previous Close | 103.08 |
| Day's Range | 102.74 - 104.40 |
| 52-Week Range | 81.10 - 104.20 |
| Beta | 0.55 |
| RSI | 69.00 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Novartis (NVS) Expands Collaboration with Argo Biopharma in $5.2B Deal
Novartis (NVS) Expands Collaboration with Argo Biopharma in $5.2B Deal
Novartis AG (NVS) Expands Strategic Collaboration with Argo Biopharma for Cardiovascular ...
Novartis AG (NVS) Expands Strategic Collaboration with Argo Biopharma for Cardiovascular Therapeutics | NVS stock news
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel ...
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases | NVS Stock News
Novartis, Argo join hands for cardiovascular assets in a deal worth up to $5.2B
Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs
Swiss drugmaker Novartis has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech ...
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate c...
Novartis: Pipeline Progress And Buyback Drive Upside
Arrowhead Pharmaceuticals (ARWR) Enters $2.2 Billion Deal with Novartis
Arrowhead Pharmaceuticals (ARWR) Enters $2.2 Billion Deal with Novartis
Arrowhead Pharmaceuticals Partners with Novartis in a Landmark $2 Billion Deal | ARWR stock news
Arrowhead Pharmaceuticals Partners with Novartis in a Landmark $2 Billion Deal | ARWR stock news
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug, sending Arrowhead stock surging.
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Pa...
Novartis (NVS) Reveals Promising V-DIFFERENCE Study Results
Novartis (NVS) Reveals Promising V-DIFFERENCE Study Results
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually opt...
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE: NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage poin...
NHS to lose out on new drugs, pharma firm warns
The claims from pharmaceutical giant Novartis comes amid a row over drug pricing deals.
Novartis and BioArctic sign collaboration and license deal
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
STOCKHOLM , Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis ...
Profits at Novartis Ireland down to 8.4m as firm raises research and development spend
Pre-tax profits at the Irish arm of Swiss-headquartered pharmaceutical giant Novartis last year declined by 25pc to 8.4m as the company increased its research and development spend.
New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen...
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis AG (NYSE: NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously trea...
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...
Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters
Swiss government to meet pharma firms to discuss US tariffs
The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...